Page last updated: 2024-11-05

thalidomide and Liposclerotic Mesenteritis

thalidomide has been researched along with Liposclerotic Mesenteritis in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

ExcerptRelevanceReference
"The median Mesenteric Panniculitis Subjective Assessment Score at baseline was 39 and at week 12 was 25 (average decrease of 44%)."2.70A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis. ( Ehrenpreis, ED; Ginsburg, PM, 2002)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ginsburg, PM1
Ehrenpreis, ED1

Trials

1 trial available for thalidomide and Liposclerotic Mesenteritis

ArticleYear
A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:12

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Sedimentation; C-Reactive Protein; Female; Foll

2002